Wednesday, June 03, 2020 7:47:06 AM
gordoncamelion wrote on 20.05.20 11:13:27 Entry No. 1.763 (63,747,802) The results from the large lung cancer study should come in Q2 2020. Here are the topics that will come this year. Upcoming Milestones We expect the company to accomplish some of the near-term milestones below: ? Q2 Clinical performance data from individual assays and in the panel combinations across the range of cancers ? Q2 / 3 Clinical data from COVID-19 studies currently underway ? Advance large-scale colorectal and lung cancer trials in Europe, Asia and the US ? Determine the level of tumor associated nucleosomes using mass spectrometry and identify NEW biomarker targets ? Q2 Utilize Nu.Q sequencing to identify tumor of origin and specific mutations ? Q3 Utilize in conjunction with Nu.Q immunoassay approach to enhance performance ? Q4 Launch Nu. Q Vet
https://www.wallstreet-online.de/diskussion/1275261-1761-1770/bluttest-krebserkennung-valitionrx-was
Recent VNRX News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 09:00:21 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/15/2026 08:05:03 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2026 08:21:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2026 08:18:53 PM
- VolitionRx Limited Announces First Quarter 2026 Financial Results and Business Update • PR Newswire (US) • 05/14/2026 08:10:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/13/2026 08:15:13 PM
- VolitionRx Limited Schedules First Quarter 2026 Earnings Conference Call and Business Update • PR Newswire (US) • 05/11/2026 12:19:00 PM
- VolitionRx Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats • PR Newswire (US) • 05/06/2026 12:17:00 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 04/30/2026 08:45:39 PM
- Volition Announces Breakthrough Finger-Prick Detection of Nucleosomes; Expanding Global Market Potential for Sepsis Testing • PR Newswire (US) • 04/29/2026 12:17:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/28/2026 09:00:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/23/2026 12:45:52 PM
- VolitionRx Announces Acceptance of Compliance Plan by NYSE American • PR Newswire (US) • 04/23/2026 12:12:00 PM
- Volition Launches rNuQ™ Webshop Broadening Product Range • PR Newswire (US) • 04/20/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/17/2026 09:00:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/01/2026 08:30:19 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2026 08:13:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/31/2026 08:12:43 PM
- VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update • PR Newswire (US) • 03/31/2026 08:05:00 PM
- VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium • PR Newswire (US) • 03/31/2026 12:16:00 PM
- Volition Announces Mayo Clinic Study Demonstrates Nu.Q® Concentrations are Elevated in Trauma Patients • PR Newswire (US) • 03/30/2026 12:13:00 PM
- Volition Announces Abstract Demonstrating Risk Stratification in Lung Cancer Presented at the European Lung Cancer Conference • PR Newswire (US) • 03/26/2026 12:17:00 PM
- VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update • PR Newswire (US) • 03/25/2026 08:12:00 PM
- Volition Announces Detection of Over 95% of Early-Stage Cancers • PR Newswire (US) • 03/25/2026 12:17:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/19/2026 08:30:29 PM
